Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
NEUP Stock Chart & Stats
$4.00
-$0.37(-10.36%)
At close: 4:00 PM EST
$4.00
-$0.37(-10.36%)
Day’s Range― - ―
52-Week Range$3.65 - $21.40
Previous CloseN/A
Volume31.57K
Average Volume (3M)89.21K
Market Cap
$21.51M
Enterprise Value-$6.14M
Total Cash (Recent Filing)$13.65M
Total Debt (Recent Filing)$85.21K
Price to Earnings (P/E)―
Beta1.61
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,377,329
10 Day Avg. Volume91,705
30 Day Avg. Volume89,214
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)<0.01
Price to Sales (P/S)0.48
P/FCF Ratio0.15
Enterprise Value/Market Cap-0.29
Enterprise Value/Revenue-0.66
Enterprise Value/Gross Profit-0.76
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$7.00Price Target Upside75.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development - PTSDPositive randomized Phase 2b PTSD data sustain development value for BNC210 and could support renewed investor interest if later-stage plans advance.
Corporate Strategy And Cash RunwayStrategic review for BNC210 together with available cash and ATM access provides flexibility to pursue transactions or funding that could enhance shareholder value into 2027.
Partnerships And CollaborationsCollaboration with Merck on an Alzheimer's candidate including MK-1167 offers potential upside through development support and external validation from a major partner.
Bears Say
Investor And Financing UncertaintyDisagreement with Lynx1 Master Fund over valuation and strategy introduces governance and financing uncertainty that may constrain strategic options and weigh on sentiment.
Loss Of Near-term CatalystLack of efficacy in the pivotal study removes a near-term catalyst for the BNC210 program and reduces clarity on upcoming development milestones.
Phase 3 Trial FailureThe Phase 3 AFFIRM-1 trial in social anxiety disorder failed to meet primary and secondary endpoints, creating a major clinical setback that can depress valuation.
Neuphoria Therapeutics News
NEUP FAQ
What was Neuphoria Therapeutics’s price range in the past 12 months?
Neuphoria Therapeutics lowest stock price was $3.65 and its highest was $21.40 in the past 12 months.
What is Neuphoria Therapeutics’s market cap?
Neuphoria Therapeutics’s market cap is $21.51M.
When is Neuphoria Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Neuphoria Therapeutics’s earnings last quarter?
Currently, no data Available
Is Neuphoria Therapeutics overvalued?
According to Wall Street analysts Neuphoria Therapeutics’s price is currently Undervalued.
Does Neuphoria Therapeutics pay dividends?
Neuphoria Therapeutics does not currently pay dividends.
What is Neuphoria Therapeutics’s EPS estimate?
Neuphoria Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuphoria Therapeutics have?
Neuphoria Therapeutics has 5,377,329 shares outstanding.
What happened to Neuphoria Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Neuphoria Therapeutics?
Currently, no hedge funds are holding shares in NEUP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
NEUP Stock 12 Month Forecast
Average Price Target
$7.00
▲(75.00% Upside)
Technical Analysis
TherapeuticsMD
―
Sintx Technologies
―
Rein Therapeutics
―
BioVie
―
BullFrog AI Holdings, Inc.
―
Ownership Overview
16.28% Insiders
0.35% Mutual Funds
0.49% Other Institutional Investors
79.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---